Protagonist Therapeutics (PTGX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics (PTGX), with a price target of $36.00. The company’s shares closed last Wednesday at $29.10, close to its 52-week high of $32.10.

According to, Tsao is a 5-star analyst with an average return of 15.1% and a 50.6% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Minerva Neurosciences.

Currently, the analyst consensus on Protagonist Therapeutics is a Moderate Buy with an average price target of $38.50.

See today’s analyst top recommended stocks >>

Based on Protagonist Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.65 million and GAAP net loss of $18.89 million. In comparison, last year the company earned revenue of $2.72 million and had a GAAP net loss of $17.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts